Hikma Pharmaceuticals PLC (FRA:H5P)
€ 22.2 0.2 (0.91%) Market Cap: 4.91 Bil Enterprise Value: 5.81 Bil PE Ratio: 27.25 PB Ratio: 2.33 GF Score: 89/100

Hikma Pharmaceuticals PLC at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 05:45PM GMT
Release Date Price: €22
James Gordon JPMorgan;Analyst

Good morning. I'm James Gordon, JPMorgan European pharma biotech analyst. And today, I've got the pleasure of introducing the Hikma presentation and we're going to hear from Hikma's new CEO, Riad Mishlawi. Thanks a lot for joining us today, Riad, and look forward to the presentation.

Riad Mishlawi
Hikma Pharmaceuticals PLC - Chief Executive Officer, Director

Thank you. All right. I had to project my voice because I'm too tall for the microphone. So good morning. Thank you very much for coming here. My name is Riad Mishlawi. Very happy to be here today. This is my first time presenting at JPMorgan in the conference.

As James has said, I've been newly appointed CEO. I've been in this role for 133 days, but who's counting? Previously, I was the President of the injectables in Hikma for quite some time. Today, I'd like to give you a brief overview of the business and our recent performance, and then set out how we are going to look at the future and our various levers for continued growth.

Just a couple of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot